Bemarituzumab( —— )

Catalog No. M36659 CAS No. 1952272-74-0

Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	301	Get Quote
5MG	511	Get Quote
10MG	820	Get Quote
25MG	1187	Get Quote
50MG	1619	Get Quote
100MG	2142	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Bemarituzumab
Note

Research use only, not for human use.
Brief Description

Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
Description

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

FGFR
Recptor

FGFR
Research Area

——
Indication

——

Chemical Information

CAS Number

1952272-74-0
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks